Vanguard Global Advisers
XENE icon

Vanguard Global Advisers’s Xenon Pharmaceuticals XENE Stock Holding History

Vanguard Global Advisers’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.8K Sell
493
-1
-0.2% -$56 ﹤0.01% 3231
2026
Q1 		$28.7K Buy
+494
New +$22.8K ﹤0.01% 3207

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Global Advisers's XENE Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Xenon Pharmaceuticals (XENE) stake by 0.2% in Q2 2026, selling an estimated $56 and leaving 493 shares worth $29.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3231.

Vanguard Global Advisers first reported a position in XENE in Q1 2026 and has held it in 2 quarters since. 310 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Vanguard Global Advisers held 493 shares of Xenon Pharmaceuticals worth $29.8K as of Q2 2026.
  • Vanguard Global Advisers sold 1 Xenon Pharmaceuticals share in Q2 2026, an estimated $56.
  • Xenon Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3231 holding.
  • Vanguard Global Advisers first reported a position in Xenon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 310 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.